News | February 05, 2022
Sun Pharma Advanced Research Company Q3FY22 loss at Rs. 15.84 crore
Sun Pharma Advanced Research Company has reported standalone financial results for the period ended December 31, 2021
Sun Pharma Advanced Research Company has reported standalone financial results for the period ended December 31, 2021
IOL Chemicals and Pharmaceuticals has reported standalone financial results for the period ended December 31, 2021
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021
Fiscal support in line with what is available in key innovation hubs such as USA and China will drive the next leg of drug discovery in India
The audit is a PAI for two of its product applications filed from this facility
In the April-September 2021 period, the FDI inflows continued to be buoyant at Rs 4,413 crore, growing at the rate of 53 per cent over the same period in 2020-21
Glenmark’s current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA
Direct to consumer pharmacy and formation as pharmacy benefit manager further mission to drastically expand access to affordable pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
